NCT01794299View on ClinicalTrials.gov

Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

September 30, 2017

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome
Interventions
BIOLOGICAL

ATIR

Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.

Trial Locations (8)

1000

Université Libre de Bruxelles - Institute Jules Bordet, Brussels

3000

Universitair Ziekenhuis Gasthuisberg, Leuven

8000

Algemeen Ziekenhuis Sint-Jan, Bruges

97080

Universitätsklinikum Würzburg, Würzburg

L8V 1C3

Juravinski Hospital and Cancer Centre, Hamilton

M5G 2M9

Princess Margaret Hospital, Toronto

H1T 2M4

Maisonneuve-Rosemont Hospital, Montreal

W12 ONN

Hammersmith Hospital, London

Sponsors

Lead Sponsor

Kiadis Pharma
All Listed Sponsors
lead

Kiadis Pharma

INDUSTRY

NCT01794299 - Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor | Biotech Hunter | Biotech Hunter